The bill
Childhood Diabetes Reduction Act of 2026
S. 5026, 119th Congress — read as touching Big-Box Retail.
Sponsored by
Sen. Sanders, Bernard [I-VT]
ID: S000033
Follow the money
The bill
S. 5026, 119th Congress — read as touching Big-Box Retail.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
20 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Department of Health and Human Services" section, p. 488-490 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 531.
July 27, 2026
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
**Summary of S. 5026: Childhood Diabetes Reduction Act of 2026**
**1. Main Purpose & Objectives** The stated purpose of S. 5026 is to combat rising rates of childhood diabetes and obesity by mandating graphic warning labels on unhealthy foods and restricting junk food advertising to children. Sponsored by Senator Bernie Sanders and reportedly amended by Senator Bill Cassidy, the bill frames itself as a public health intervention. However, the real objective appears to be performative legislating—allowing lawmakers to claim they’re “doing something” about childhood diabetes while avoiding meaningful action on the root causes: agricultural subsidies for corn syrup, school lunch programs dominated by processed foods, and the socioeconomic realities that make healthy eating inaccessible to low-income families. It’s a placebo bill for a systemic illness.
**2. Key Provisions & Changes to Existing Law** The bill amends the Federal Food, Drug, and Cosmetic Act to require FDA-mandated warning labels on: - Sugar-sweetened beverages (with labels warning of obesity, type 2 diabetes, and tooth decay) - Foods/beverages containing high-intensity sweeteners (e.g., aspartame, sucralose) - Ultra-processed foods (linked to weight gain and diabetes risk) - Any food high in “nutrients of concern” (added sugar, saturated fat, sodium), as determined by the Secretary of HHS
Labels must be bold, enclosed in geometric borders (rectangle or octagon), accompanied by an exclamation-in-triangle icon, and occupy at least 5% of the principal display panel—including multi-pack sides and online retail listings. It also restricts junk food advertising to children and requires disclosures of warning labels in ads, empowering the FTC to enforce these rules—effectively reviving dormant authority over children’s marketing that was neutered decades ago.
**3. Affected Parties & Stakeholders** - **Food and Beverage Industry:** Forced to redesign packaging, absorb compliance costs, and face potential sales declines—especially for sugary drinks, cereals, and snack foods. Expect lobbying, lawsuits, and “reformulated” products that swap sugar for equally dubious sweeteners to skirt labels. - **Advertisers & Media Companies:** Restricted from marketing unhealthy foods to kids—impacting Nickelodeon, Cartoon Network, YouTube kids’ content, and influencer deals. Cue outrage over “nanny state” overreach. - **Parents & Children:** Supposed beneficiaries, but labels may confuse rather than educate, and advertising restrictions won’t stop kids from seeing ads during adult programming or on unregulated platforms like TikTok. - **FDA & FTC:** Burdened with enforcement—yet another unfunded mandate slapped on agencies already overwhelmed by food safety and antitrust crises. - **Public Health Advocates:** Will cheer, unaware they’re celebrating a bandaid on a hemorrhage.
**4. Potential Impact & Implications** Impact will be minimal. Warning labels have shown mixed results elsewhere (e.g., Chile’s black octagons reduced sugary drink purchases modestly, but obesity rates remain high). Here, industry will exploit loopholes: reformulating with artificial sweeteners (which get their own warning), shrinking serving sizes to avoid thresholds, or shifting marketing to parents (“whole grain!” labels on sugar-coated cereal). The advertising restrictions may face First Amendment challenges, and online enforcement will be a joke—try policing influencer snack hauls on TikTok. Ultimately, this bill treats symptoms while ignoring the disease: a food system engineered for profit, not health. It’s legislative theater—letting Congress feel virtuous while Big Food laughs all the way to the bank. If passed, it’ll achieve little beyond enriching label designers and giving politicians a prop for reelection ads. Childhood diabetes won’t drop—it’ll just get a new warning label.
Sen. Sanders, Bernard [I-VT]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No organization contributions found
No committee contributions found
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 32 nodes and 47 connections
Total contributions: $47
Showing top 13 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 3 harmed.
Section 101(a) requires warning labels on certain foods and beverages, which may lead to decreased sales for big-box retailers that sell these products
Section 101(a) requires warning labels on certain foods and beverages, which may lead to decreased sales for restaurants and food service providers that serve these products
Section 101(a) requires warning labels on certain foods and beverages, which may lead to decreased demand for ingredients used in these products, potentially harming agribusiness companies
For each industry this bill affects, here's what the sponsor (Sen. Sanders, Bernard [I-VT])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
AI Analysis:
"The bill focuses on childhood diabetes prevention through food labeling and advertising restrictions, while the Project 2025 HHS section emphasizes abortion data reporting, gender identity data collection opposition, FDA regulatory reforms, drug shortages, and abortion pills—with no substantive overlap in policy objectives or mechanisms."
— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days
AI Analysis:
"The bill focuses on childhood diabetes prevention through food labeling and advertising restrictions, while the Project 2025 excerpt discusses USDA farm subsidies, crop insurance, and the reorganization of nutrition programs—there is minimal thematic overlap beyond a general concern for public health and nutrition."
— 297 — Department of Agriculture losses, which is another way of saying minor dips in expected revenue. This is hardly consistent with the concept of providing a safety net to help farmers when they fall on hard times. The Congressional Budget Office (CBO), in one of its options to reduce the federal deficit, has once again identified repealing all Title I farm programs, including ARC, PLC, and the federal sugar program.46 l Stop paying farmers twice for price and revenue losses during the same year. Farmers can receive support from the ARC or PLC programs and the federal crop insurance program to cover price declines and revenue shortfalls during the same year. Congress should prohibit this duplication by prohibiting farmers from receiving an ARC or PLC payment the same year they receive a crop insurance indemnity. l Reduce the premium subsidy rate for crop insurance. On average, taxpayers cover about 60 percent47 of the premium cost for policies purchased in the federal crop insurance program. One of the most widely supported and bipartisan policy reforms is to reduce the premium subsidy that taxpayers are forced to pay.48 At a minimum, taxpayers should not pay more than 50 percent of the premium. After all, taxpayers should not have to pay more than the farmers who benefit from the crop insurance policies. CBO has found that reducing the premium subsidy to 47 percent would save $8.1 billion over 10 years and have little impact on crop insurance participation or on the number of covered acres.49 In that analysis, there would be a reduction in insured acres of just one-half of 1 percent, and only 1.5 percent of acres would have lower coverage levels. 50 This reform is basically all benefit with little to no cost. In its recently released report identifying options to reduce the federal deficit, CBO found that reducing the premium subsidy to 40 percent would save $20.9 billion over 10 years.51 Beyond these legislative reforms, the next Administration should: l Communicate to Congress the necessity of transparency and a genuine reform process. The White House and the USDA should make it very clear that the farm bill process, including reform of farm subsidies, must be con- ducted through an open process with time for mark-up and the opportunity for changes to be made outside the Agriculture Committee process. The farm bill too often is developed behind closed doors and without any chance for real reform. The White House, given the power of the bully pulpit, — 298 — Mandate for Leadership: The Conservative Promise must demand a genuine reform process and express unwavering support for a USDA that shapes a safety net that considers the interests of farmers, while also remembering the interests of taxpayers and consumers. Any safety net for farmers should be a true safety net—one that helps farmers when they have experienced serious unforeseen losses (preferably when there has been a disaster or unforeseen natural event causing damage) and that exists to help them in unusual situations. l Separate the agricultural provisions of the farm bill from the nutrition provisions. To have genuine reform and proper consideration of the issues, agricultural programs should be considered in separate legislation distinct from food stamps and the nutrition part of the farm bill, and reauthorization of such programs should be fixed on different timelines to ensure this separation. Agricultural and nutritional programs, which are distinct from each other, have been combined together for political reasons, something which is readily admitted by proponents of this logrolling. When it comes to American agriculture and welfare programs, they deserve sound policy debates, not political tactics at the expense of thoughtful discourse. Move the Work of the Food and Nutrition Service. The USDA implements many means-tested federal support programs, including the largest food assis- tance program, Supplemental Nutrition Assistance Program (SNAP, also known as food stamps), and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Food Program. The Food and Nutrition Service (FNS) oversees these programs and other food and nutrition programs, including the Center for Nutrition Policy and Promotion,52 which handles the USDA’s work on the “Dietary Guidelines for Americans” (Dietary Guidelines).53 Food nutrition programs include: SNAP; WIC; the National School Lunch Program (NSLP); the School Breakfast Program (SBP); the Child and Adult Care Food Program; the Nutrition Program for the Elderly; Nutrition Service Incentives; the Summer Food Service Program; the Commodity Supplemental Food Program; the Temporary Emergency Food Program; the Farmer’s Market Nutrition Program; and the Spe- cial Milk Program. The next Administration should: l Move the USDA food and nutrition programs to the Department of Health and Human Services. There are more than 89 current means- tested welfare programs, and total means-tested spending has been estimated to surpass $1.2 trillion between federal and state resources.54 Because means-tested federal programs are siloed and administered in separate agencies, the effectiveness and size of the welfare state remains
AI Analysis:
"The bill focuses on warning labels and advertising restrictions to combat childhood diabetes and obesity, while the Project 2025 policy emphasizes reducing federal overreach in school meal programs and re-evaluating regulations like those for baby formula. There is minimal thematic overlap, as the bill expands federal labeling requirements, whereas Project 2025 seeks to scale back such regulations."
— 302 — Mandate for Leadership: The Conservative Promise l Re-evaluate excessive regulation. As for baby formula regulations generally, labeling regulations and regulations that unnecessarily delay the manufacture and sale of baby formula should be re-evaluated.80 During the Biden Administration, there have been devastating baby formula shortages. Return to the Original Purpose of School Meals. Federal meal programs for K–12 students were created to provide food to children from low-income families while at school.81 Today, however, federal school meals increasingly resemble enti- tlement programs that have strayed far from their original objective and represent an example of the ever-expanding federal footprint in local school operations. The NSLP and SBP are the two largest K–12 meal programs provided by federal taxpayer money. The NSLP launched in 1946 and the SBP in 1966, both as options specifically for children in poverty.82 During the COVID-19 pandemic, federal policymakers temporarily expanded access to school meal programs, but some lawmakers and federal officials have now proposed making this expansion per- manent.83 Yet even before the pandemic, research found that federal officials had already expanded these programs to serve children from upper-income homes, and these programs are rife with improper payments and inefficiencies. Heritage Foundation research from 2019 found that after the enactment of the Community Eligibility Provision (CEP) in 2010, the share of students from middle- and upper-income homes receiving free meals in states that participated in CEP doubled, and in some cases tripled—all in a program meant for children from families with incomes at or below 185 percent of the federal poverty line (Children from homes at or below 130 percent of the federal poverty line are eligible for free lunches, while students from families at or below 185 percent of poverty are eligible for reduced-priced lunches).84 Under CEP, if 40 percent of students in a school or school district are eligible for federal meals, all students in that school or district can receive free meals. However, the USDA has taken it even further, improperly interpreting the law85 to allow a subset of schools within a district to be grouped together to reach the 40 percent threshold, As a result, a school with zero low-income students could be grouped together with schools with high levels of low-income students, and as a result all the students in the schools within that group (even schools without a single low-in- come student) can receive free federal meals.86 Schools can direct resources meant for students in poverty to children from wealthier families. Furthermore, the NSLP and SBP are among the most inaccurate federal programs according to PaymentAccuracy.gov, a project of the U.S. Office of Man- agement and Budget and the Office of the Inspector General.87 Before federal auditors reduced the rigor of annual reporting requirements in 2018, the NSLP had wasted nearly $2 billion in taxpayer resources through payments provided to ineligible recipients.88 Even after the auditing changes, which the U.S. Government
Showing 3 of 5 policy matches
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.
A joint resolution providing for congressional disapproval of the proposed foreign military sale to Israel of certain defense articles and services.
119/sjres/26
A joint resolution providing for congressional disapproval of the proposed foreign military sale to the Government of Israel of certain defense articles and services.
119/sjres/34
A joint resolution providing for congressional disapproval of the proposed export of certain defense articles to Israel.
119/sjres/41